GlassScriptPhysician profile
Jeffrey A Carr
NPI 1114916814
$865.95
in general payments reported to CMS, 2019-2025
13 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $62.51 · 2021: $19.03 · 2022: $60.37 · 2023: $190 · 2024: $192 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $486.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $274.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $165.29 | 2019-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $97.18 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Pfizer INC. | $72.30 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $67.18 | 2019 | |
| Amarin Pharma, INC. | $31.45 | 2019-2020 | |
| Novo Nordisk INC | $30.83 | 2019-2020 | |
| Sanofi Pasteur INC. | $27.21 | 2019 | |
| Ucb, INC. | $25.34 | 2023 | Fintepla |
| Dynavax Technologies Corporation | $23.91 | 2024 | Heplisav-B |
| Lilly USA, LLC | $20.84 | 2024 | Mounjaro |
| Abbvie INC. | $19.03 | 2021 | |
| Phadia US INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.